綠康生化(002868.SZ):控股股東及5%以上股東參設1億元寵物產業併購基金
格隆匯11月21日丨綠康生化(002868.SZ)公佈,公司於近日接到公司控股股東上海康怡及持股5%以上股東富傑平潭的通知,為協助推進公司總體戰略,為公司獲得潛在的寵物醫藥、動物疫苗等相關領域的優質企業併購機會爭取先機,降低公司因直接介入產業併購整合可能面臨的風險,上海康怡使用4590萬元、富傑平潭使用510萬元與華興創業使用2400萬元、南平綠色產投使用2400萬元、華興康平管理公司使用100萬元,共同設立福建平潭創新之元寵物產業投資合夥企業(有限合夥),並簽署基金合夥協議,產業併購基金規模為1億元,上海康怡和富傑平潭為有限合夥人,該基金的管理人為華興康平管理公司,基金將重點投向高成長性的、具備較高投資回報潛力的寵物醫藥、動物疫苗等相關領域。
截至2019年11月21日,創新之元產業併購基金已經取得由平潭綜合實驗區市場監督管理局下發的營業執照。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.